Leaflet OXALIPLATIN STADA 5mg / ml powder infusion solution


Indicated for: colorectal cancer

Route of administration: infusion

Substance: oxaliplatin (antineoplastic agent)

ATC: L01XA03 (Antineoplastic and immunomodulating agents | Other antineoplastic agents | Platinum compounds)

Oxaliplatin is a chemotherapy agent used in the treatment of advanced or metastatic colorectal cancer. It works by binding to the DNA of tumor cells, inhibiting their replication and causing cell death.

The medication is administered intravenously, as directed by a doctor, usually in combination with other chemotherapy drugs. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as peripheral neuropathy, nausea, or diarrhea. It is important to inform the doctor of any unusual symptoms.

Common side effects include peripheral neuropathy, nausea, and diarrhea. In rare cases, severe reactions such as myelosuppression or allergic reactions may occur. Patients should be informed of these risks before use.

General data about OXALIPLATIN STADA 5mg / ml

  • Substance: oxaliplatin
  • Date of last drug list: 01-01-2019
  • Commercial code: W52977001
  • Concentration: 5mg / ml
  • Pharmaceutical form: powder infusion solution
  • Quantity: 1
  • Product type: generic
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: CELL PHARM GMBH - GERMANIA
  • Holder: STADA ARZNEIMITTEL AG - GERMANIA
  • Number: 4202/2012/01
  • Shelf life: 4 years-after packing for marketing; dupa dilutie-24 h la frigider (2-8°C)